Requested symbol wasn't found

U.S. Markets closed
Loading...
Loading...
  • PR Newswire3 months ago

    Avanir Pharmaceuticals Appoints Richard Malamut, MD, as Senior Vice President, Research & Development, and Chief Medical Officer

    ALISO VIEJO, Calif., Nov. 29, 2016 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that Richard Malamut, MD, has joined the company as senior vice president, research and development, and chief medical officer. Dr. Malamut will lead a seasoned and experienced team working to expand Avanir from a company with two FDA-approved products – NUEDEXTA® and ONZETRA Xsail® – to a leading CNS company with therapies in several neurological conditions with few, if any treatment options. The company is currently investigating treatments in the areas of agitation in Alzheimer's disease, schizophrenia and other neurological conditions.

  • PR Newswire8 months ago

    Avanir Pharmaceuticals to Present Data on ONZETRA™ Xsail™ at American Headache Society (AHS) 2016 Annual Scientific Meeting

    ALISO VIEJO, Calif., June 9, 2016 /PRNewswire/ --  Avanir Pharmaceuticals , Inc. today announced that the company will be presenting results from several studies about ONZETRA™ Xsail™ (sumatriptan nasal ...

  • PR Newswire9 months ago

    NUEDEXTA® Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury

    ALISO VIEJO, Calif., June 8, 2016 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced the publication of full results from the PRISM II study, which demonstrated significant improvement of pseudobulbar affect (PBA) following treatment with NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules in patients with Alzheimer's disease (AD) and other dementias, stroke and traumatic brain injury (TBI). PBA is a condition characterized by sudden and uncontrollable outbursts of crying and/or laughing resulting from certain neurologic diseases or brain injury. NUEDEXTA is the only pharmaceutical agent approved by the U.S. Food and Drug Administration for the treatment of PBA.